Ivabradine reduces myocardial infarction and revascularization in coronary patients with HR>70 bpm

Published: 2008-09-16 06:23:00

Updated: 2008-09-16 06:23:00

The results of the BEAUTIFUL (Morbidity-Mortality Evaluation of the Inhibitor Ivabradine in Patients with Coronary Disease and Left Ventricular Dysfunction) study, presented at the ESC 2008 and published in the Lancet, have demonstrate that ivabradine reduces myocardial infarction and revasculari...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK